Yongzitang, a private pharmaceutical enterprise established at the beginning of the new century, passed the GMP certification of the US Food and Drug Administration on July 6, 2004. In 2005, the long-term development plan of "building the core competitiveness of enterprises and taking the road of brand development" was formulated. After several years of rapid development, Yongzitang Company has owned many patents, complete gastrodia elata product line and systematic innovation mechanism, and has grown into a leading enterprise in Zhaotong gastrodia elata industry. Her strong development momentum has promoted the optimization and upgrading of the whole industrial structure and the rapid change of development mode, which fully embodies the medicinal and economic value of Zhaotong Gastrodia elata. Yongzitang Company successfully transformed Zhaotong Gastrodia elata's resource advantages into economic advantages and regional competitive advantages through the operation of the national market, which enabled Zhaotong Gastrodia elata to successfully realize a great turning point from low-end edible products to high-end medicinal products. Today, a modern gastrodia elata medicinal material deep processing base facing the whole country, the world and the future stands proudly on the land of Wumeng.

? What makes Yongzitang develop steadily step by step in the fierce competitive market, in the pain of industry reform and in the complex medical policy environment? It is a simple and excellent corporate culture, a people-oriented management concept, a pragmatic work style, Zhaotong Gastrodia elata with excellent quality, a consistent standard quality, a professional and dedicated employee, an innovative spirit of advancing with the times, an excellent Zhaotong land and real government support. In a word, Yongzitang has experienced too many storms, precipitated too many stories and achieved impressive results. Every step of her development has witnessed the growth mileage of private pharmaceutical enterprises in Yunnan in the new period. Let's follow the interview of Tian Guanglin, a special correspondent of this newspaper, solve the mystery one by one and explore the development path of private pharmaceutical enterprises in Yunnan in the new period.

Yongzitang will be rooted in Zhaotong, based in Yunnan, facing the whole country, and become an enterprise with intellectual property rights and sustainable development.

Interview with Mr Zheng, General Manager of Yunnan Yongzitang Pharmaceutical Co., Ltd.

? On June 6th, 2007, 65438+February 6th, the 58th National Drug Fair was held in Kunming. In the exhibition center, Yongzitang Company exhibited unusually in the general exhibition area, which showed me a unique enterprise. At the exhibition, I met Mr. Zheng, the general manager of the company, and invited him to accept our interview. He agreed happily.

Tian Guanglin: Mr. Zheng, why did you set up a pharmaceutical factory in Zhaotong?

Zheng: I understand your question, because in people's impression, Zhaotong is a poor area with inconvenient transportation and underdeveloped economy, and it seems that its reputation is not very good. According to the general rule, all investments and factories should be in economically developed areas, but why did we choose Zhaotong? It is because we have taken a fancy to Zhaotong's huge resource advantages and the efficient medicinal value of Zhaotong Gastrodia elata. Zhaotong area is rich in green mountains and black soil, and has the reputation of "golden triangle" of resources, with great development potential. The reserves of lignite in Zhaotong Basin rank second in South China. Yunnan is rich in hydropower resources, and three state-level giant power stations, Xiluodu, Xiangjiaba and Baihetan, are under construction. There are many kinds of biological resources, and it is the largest high-quality apple base in southern China. Zhaotong Gastrodia elata, Eucommia ulmoides Oliv., Amorphophallus konjac, Zanthoxylum bungeanum, Kudingcha and other specialty products are famous both inside and outside the province. The transportation is convenient now. After the expressway is opened to traffic, it only takes more than 4 hours from Kunming to Zhaotong. In this environment, enterprises will have the motivation to develop.

Tian Guanglin: Mr. Zheng, can you tell us something about this pharmaceutical factory?

Zheng: The company officially passed the national GMP certification on July 6, 2004. In 2005, the company formulated a long-term development plan of "building the core competitiveness of enterprises and taking the road of brand development". After several years of rapid development, Yongzitang has become a leading enterprise in Zhaotong Gastrodia elata industry. The company's strong development momentum has promoted the optimization and upgrading of the whole industrial structure and the rapid change of development mode, which fully embodies the medicinal and economic value of Zhaotong Gastrodia elata. Yongzitang has successfully transformed the resource advantage of Zhaotong Gastrodia elata into economic advantage and regional competitive advantage by operating the national market.

Tian Guanglin: Mr. Zheng, what gastrodia elata products does the company mainly have now?

Zheng: Yongzitang Company made use of various social resources, market-oriented, combined with Industry-University-Research, seized the important strategic opportunity of medical reform, responded to risk challenges, carried forward the spirit of seeking truth from facts and pioneering spirit, and scientifically developed ethnic medicine. In a short time, it developed a complete product line of Zhaotong Gastrodia elata, including drugs: Tianma Xingnao capsules, health care products: Gastrodia elata micropowder capsules, and original hemp products: Zhaotong super-grade Gastrodia elata produced by Yongzitang. Tianma Xingnao Capsule was awarded the national invention patent certificate by China National Intellectual Property Administration on May 3rd, 20061. All these have laid a solid foundation for the development of gastrodia elata industry in Yongzitang and Zhaotong.

Tian Guanglin: Mr. Zheng, I saw your company's "persistent pursuit" at the National Medicine Conference. Public health ",can you introduce the corporate culture of the company in detail?

Zheng: At the beginning of the establishment of Yongzitang Company, it put forward "all health" and "harmony first". Integrity-oriented "business philosophy and" persistent pursuit? Public health "corporate mission. Yongzitang Company has always adhered to the enterprise tenet of "all for health", which has enabled the company to develop steadily step by step in the fierce market competition, the pain of industry reform and the complex medical policy environment. It is based on "harmony first? Under the guidance of the "honesty-oriented" business philosophy, Yongzitang people have established a good reputation and market credit in the highly competitive pharmaceutical market, and constantly enhanced the brand value of Yongzitang.

Tian Guanglin: Mr. Zheng, can you summarize the future development ideas of the following companies?

Zheng: Yongzitang will be rooted in Zhaotong, based in Yunnan, facing the whole country, be an enterprise with intellectual property rights and sustainable development, actively carry out the construction of gastrodia elata industrial chain with enterprises+bases+farmers, adhere to scientific development, innovate development concepts, improve development quality and efficiency, build a resource-saving enterprise, promote the preservation and appreciation of Yongzitang brand, promote the harmony between labor and capital, achieve sound and rapid development of enterprises, and strive to build a gastrodia elata industrial kingdom based in Zhaotong. In short, the company will advance along the strategic direction of "consolidating the survival foundation, accelerating the development speed and enhancing the brand value", and build the company into an enterprise with distinctive features, strong competitiveness and vitality, so that Zhaotong Gastrodia elata can go global and benefit all mankind.

In the "consumer-centered" marketing era, the interests of consumers are always the first, and Yongzitang firmly believes that this is the truth.

Interview with Mr. Luo Xudong, Vice President of Marketing of Yunnan Yongzitang Pharmaceutical Co., Ltd.

? I met Vice President Luo at the 57th National Drug Fair in Shenzhen. He is leading the staff of customer service department to set up the booth. We talked a few words, and seeing that he was busy, we didn't bother him again. After the meeting, we started our interview on a pleasant afternoon.

Tian Guanglin: Innovation is the core driving force for the sustainable development of enterprises. What innovations has Yongzitang made in its development?

Vice President Luo: Yongzitang has realized that talent innovation is the foundation, management innovation is the soul, marketing innovation is the lifeline, and technological innovation is the core and cornerstone. It is the unremitting pursuit of innovation that Yongzitang developed Tianma Xingnao Capsule with high-quality Zhaotong Tianma, which can effectively treat headache, dizziness, insomnia, hypomnesia and slow response, and was awarded the national invention patent by China National Intellectual Property Administration on May 3, 2006. Yongzitang has invested heavily in scientific research. In order to study the pharmacology and safety of Tianma Xingnao Capsule, the company cooperated with Yunnan Provincial Key Laboratory of Natural Medicine Pharmacology for three years, and finally came to the conclusion that Tianma Xingnao Capsule can effectively anticoagulant, antithrombotic, anti-ischemic, increase cerebral blood flow, increase blood-brain permeability, improve microcirculation, increase blood supply to brain tissue, and has good effects of improving intelligence, promoting blood circulation, removing blood stasis, calming and hypnotizing.

Tian Guanglin: Can you tell us something about the market situation of Tianma Xingnao Capsule?

Vice President Luo: The research and development of Tianma Xingnao Capsule is forward-looking. At present, China has entered an aging society, and the elderly population over 65 has reached 65438+35 million, accounting for 10% of the world. Among them, 13.6% of the elderly suffer from cerebrovascular diseases, with high mortality, recurrence and disability rates. Therefore, cardiovascular and cerebrovascular diseases have become the first killer threatening the elderly. The research and development of Tianma Xingnao Capsule is based on the in-depth understanding of this market. Practice has proved that the research and development of Tianma Xingnao Capsule embodies the innovative spirit and social responsibility of Yongzitang people. Tianma Xingnao Capsule has sold more than 8 million boxes since its listing, and received letters from nearly 10,000 patients all over the country, which greatly praised it and produced good economic and social benefits.

Tian Guanglin: Can you tell us something about the brand building of Yongzitang Company?

Vice President Luo: In the final analysis, the core competitiveness of an enterprise is a brand, which is built by quality and credibility. Quality and reputation are the core and soul of an enterprise, and product quality is the most important cornerstone for an enterprise to build a brand. Yongzitang people regard product quality as the life of the company, and every product produced is produced in strict accordance with the national GMP good manufacturing practices. The company's preparation workshop is the core of the pharmaceutical factory, completely isolated from the outside world. The water and air here must be strictly filtered and purified by air conditioning purification system and process water system. In order to ensure the quality of drugs, the air cleanliness here is very clean, generally staying above 300,000, and reaching 1 10,000 in some places. The company uses dust particle counter, anemometer and other testing instruments to monitor the cleanliness regularly, and also monitors the settling bacteria, so that all indicators can reach GMP? Requirements. Yongzitang relies on this persistent demand for product quality and a responsible attitude towards consumers. Since the product went on the market, there has been no customer complaint caused by quality problems, and Tianma Xingnao Capsule has not been filed in the ADR Center of the State Administration of Pharmaceutical Products, which is very rare for a new drug.

Tian Guanglin: Tell me about your feelings about Yongzitang Company in the past five years.

Vice President Luo: Looking back on the hard course of the company's five-year development, Yongzitang has achieved staged victory from the establishment of the company to the formulation of development strategy, from product research and development to market development, from scientific research investment to property rights protection, from corporate culture construction to brand value promotion. Looking forward to the future, the development of these five years is only a small node that has created the glory of Yongzitang for a hundred years, and there are more and longer ways to go forward for Yongzitang people. Yongzitang people firmly believe that through the efforts of Yongzitang people, relying on Zhaotong's good social environment and resource advantages, relying on scientific and technological innovation and market development, and adhering to the direction of corporate culture, we will certainly achieve the development goal of Yongzitang, make greater contributions to the upgrading and growth of Zhaotong's gastrodia elata industry and Zhaotong's economic development, and fulfill the historical responsibility of our generation in the "Hundred Years of Glory of Yongzitang".

In the "consumer-centered" marketing era, the interests of consumers are always the first. Therefore, Yongzitang Company has specially set up a toll-free customer service telephone number of 800-889-5899 to answer patients' calls. The company also tracks the flow of each box of drugs through strict multi-channel anti-counterfeiting procedures, ensuring the interests of partners and consumers, and truly achieving the business goal of "* * * creating, * * * winning, * * * enjoying". The interview activity of Yongzitang Company is over, and what is displayed in front of us is the majestic momentum of the Yangtze River flowing eastward.

There are many drugs to treat recurrent headache, dizziness and insomnia, but we should choose the right one.

-Interview with Chief Physician Wang Xiaohua of Jinan First People's Hospital.

? In modern cities, in order to adapt to the competitive environment, the pace of life and work is obviously accelerated, and the pressure of work and study is also increasing, so headaches, dizziness and insomnia are more prominent and common. Headache, dizziness and insomnia are not minor problems. Frequent headaches, dizziness and insomnia will seriously affect people's life, work and study. If not treated in time, there will be serious sequelae, and the consequences will be unimaginable. On this issue, we interviewed Wang Xiaohua, chief physician of Jinan First People's Hospital:

Tian Guanglin: Dr. Wang, please tell us about the frequent headaches, dizziness and insomnia first.

Dr. Wang: Modern medical research has found that the main causes of frequent headaches, dizziness and insomnia are: various pathological diseases inside and outside the brain, functional diseases of organs, excessive brain use, anger, high mental stress, neurological dysfunction of the brain, vasospasm and intracranial blood circulation disorder, leading to blood stasis and qi stagnation, and insufficient blood supply and oxygen supply to the brain. Scientific research shows that if the brain has insufficient blood supply and oxygen supply for a long time, the brain function will not be improved, and the condition will gradually deepen, which can induce sequelae such as cerebral hemorrhage, paralysis, psychosis, dementia and brain tumor.

Tian Guanglin: What will happen if you don't treat the recurrent headache, dizziness and insomnia in time?

Dr. Wang: There are many people who die of cerebral hemorrhage and cerebral infarction due to frequent headaches, dizziness and insomnia. According to one data, one person dies of cardiovascular and cerebrovascular diseases every 12 seconds in China. In recent years, while discussing the relationship between qi and blood and the cause of death? It is found that brain diseases such as cerebral hemorrhage, cerebral infarction and brain atrophy are directly related to "blood stasis". Generally accompanied by thrombosis tendency, such as thrombocytosis. Frequent headaches, dizziness and insomnia indicate that the arteries supplying blood and nutrition to the brain have been blocked by 80% due to sclerosis; Vascular sclerosis and thickening of the vascular wall will inevitably lead to stenosis of the lumen, which will make the blood flowing to the brain seriously insufficient and cannot meet the normal work of the brain. If left unchecked, blood vessels will further harden, narrow and block, and if hardened plaques fall off, blood vessels will be infarcted, leading to cerebral infarction. Therefore, frequent headaches, dizziness and insomnia are no longer minor illnesses. It is not a problem that can be solved by taking painkillers.

Tian Guanglin: Have you ever encountered any serious cases caused by repeated headaches, dizziness and insomnia without timely treatment?

Dr. Wang: Yes, an old teacher failed to treat her frequent headaches, dizziness and insomnia in time, which caused serious consequences. Teacher Zhang is 50 years old and has been suffering from headache, dizziness and insomnia. His wife advised him to go to the hospital for a careful examination several times, but he wouldn't listen. He always lets his wife pinch his headache and dizziness. If he can't, he will take some painkillers. A few days ago, Mr. Zhang suddenly had a bad headache after dinner and died on the way to the hospital. After examination by the hospital, Teacher Zhang died of cerebral hemorrhage.

Dr. Wang: There are many drugs on the market to treat recurrent headache, dizziness and insomnia, but we should choose the right one. We suggest that it is best to use pure Chinese medicine preparation, which will not damage liver and kidney and will not produce physical and mental dependence. Such as Yongzitang Tianma Xingnao Capsule. Here, I especially remind middle-aged and elderly friends and friends with elderly people at home not to despise frequent headaches, dizziness and insomnia, which are considered as minor problems. Just bear it and it will pass. Perhaps this is a harbinger of cerebral hemorrhage, cerebral infarction and brain atrophy. We should pay more attention to it and take time to treat it, so as not to induce serious brain diseases such as brain dementia. Therefore, people who think they are healthy already have some symptoms (such as frequent headache, dizziness and insomnia), and it is very likely that they will have cerebral hemorrhage or cerebral infarction like Teacher Zhang.

Tian Guanglin: What medicine is Tianma Xingnao Capsule and what is its pharmacological effect?

Dr. Wang: Tianma Xingnao Capsule is a pure Chinese medicine preparation, which is made of Zhaotong genuine Gastrodia elata as raw material, supplemented with five precious Chinese medicines: earthworm, Acorus gramineus, polygala tenuifolia, Radix Rehmanniae Preparata and Cistanche deserticola. Has the effects of nourishing liver and kidney, calming liver, calming endogenous wind, dredging collaterals and relieving pain. Proved by Yunnan Provincial Key Laboratory of Natural Medicine, Tianma Xingnao Capsule has good effects of improving intelligence, promoting blood circulation and removing blood stasis, calming and hypnotizing, effectively resisting coagulation and thrombosis, improving cerebral blood flow, increasing blood-brain permeability, improving microcirculation and increasing blood supply to brain tissue, and has obvious anti-platelet aggregation effect, which has a strong preventive effect on cerebral thrombosis, and is beneficial to preventing and treating thromboembolic diseases with increased platelet aggregation and preventing cerebral blood supply and nutrient artery blockage caused by sclerosis.